J. Liu

发表

Discovery and optimization of a novel series of liver X receptor-α agonists

J. Medina, B. Shan, Bei Shan, 2006 .

Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.

Feng Xu, T. Schall, Qingge Xu, 2007, Bioorganic & medicinal chemistry letters.

AMG 837: a potent, orally bioavailable GPR40 agonist.

Ying Sun, J. Reagan, Rajiv Sharma, 2012, Bioorganic & medicinal chemistry letters.

SGLT2 Inhibitors for Type 2 Diabetes

J. Liu, TaeWeon Lee, 2011 .

Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.

P. Coward, N. Walker, Zhulun Wang, 2014, Bioorganic & medicinal chemistry letters.

Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1

S. Wong, M. Schwarz, H. Baribault, 2013, Molecular and Cellular Endocrinology.

The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.

S. Wong, Yang Li, R. Schwandner, 2010, Bioorganic & medicinal chemistry letters.

Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists.

E. Rickel, W. Shen, Michael G. Johnson, 2012, Bioorganic & medicinal chemistry letters.

Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.

J. Reagan, M. Lizarzaburu, M. Yamazaki, 2013, ACS medicinal chemistry letters.

ASYMMETRIC SYNTHESIS OF DIFFERENTIALLY PROTECTED 2,7-DIAMINOSUBERIC ACID, A RING-CLOSURE METATHESIS APPROACH

Robert M. Williams, J. Liu, 1998 .

Discovery and optimization of CRTH2 and DP dual antagonists.

T. Sullivan, G. Tonn, J. Medina, 2009, Bioorganic & medicinal chemistry letters.

Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism.

E. Rickel, W. Shen, Xuemei Wang, 2012, Bioorganic & medicinal chemistry letters.

Benzodiazepinone Derivatives as CRTH2 Antagonists.

A. Cheng, J. Medina, J. Liu, 2011, ACS medicinal chemistry letters.

Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.

Qingge Xu, W. Shen, T. Sullivan, 2011, ACS medicinal chemistry letters.

Optimization of GPR40 Agonists for Type 2 Diabetes.

Sean P. Brown, Ying Sun, Rajiv Sharma, 2014, ACS medicinal chemistry letters.

Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.

P. Coward, J. Medina, B. Shan, 2014, Bioorganic & medicinal chemistry letters.

Optimization of a series of quinazolinone-derived antagonists of CXCR3.

T. Sullivan, G. Tonn, Andrew P. Marcus, 2009, Bioorganic & medicinal chemistry letters.

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Y. Wang, J. Canon, M. Peterson, 2014, Journal of medicinal chemistry.

Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.

Sean P. Brown, J. Medina, M. Bartberger, 2013, ACS medicinal chemistry letters.

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.

B. Lemon, T. Sullivan, G. Tonn, 2008, Bioorganic & medicinal chemistry letters.

Identification and Functional Characterization of Allosteric Agonists for the G Protein-Coupled Receptor FFA2

Yang Li, R. Schwandner, J. Liu, 2008, Molecular Pharmacology.

Discovery of the imidazole-derived GPR40 agonist AM-3189.

Rajiv Sharma, Zhihua Ma, G. Tonn, 2016, Bioorganic & medicinal chemistry letters.

Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?

Ralph A. DeFronzo, R. DeFronzo, J. Liu, 2012, Diabetes.

Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Sean P. Brown, J. Medina, Thanhvien Tran, 2014, ACS medicinal chemistry letters.

Discovery of non-glucoside SGLT2 inhibitors.

Jian Zhang, An-Rong Li, Joanne Greenberg, 2011, Bioorganic & medicinal chemistry letters.

Identification and Functional Characterization of Allosteric Agonists for the G Protein-Coupled Receptor FFA 2

Yang Li, R. Schwandner, J. Liu, 2008 .

Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.

Xin Huang, Paul Shaffer, Daqing Sun, 2014, ACS medicinal chemistry letters.

Asymmetric Synthesis of Differentially Protected 2,7‐Diaminosuberic Acid, a Ring‐Closure Metathesis Approach.

Robert M. Williams, J. Liu, 1998 .

Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.

P. Coward, J. Medina, J. Eksterowicz, 2013, Bioorganic & medicinal chemistry letters.

AMG 837: a potent, orally bioavailable GPR40 agonist.

Ying Sun, J. Reagan, Rajiv Sharma, 2012, Bioorganic & medicinal chemistry letters.

Optimization of GPR40 Agonists for Type 2 Diabetes.

Sean P. Brown, Ying Sun, Rajiv Sharma, 2014, ACS medicinal chemistry letters.

Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Sean P. Brown, J. Medina, Thanhvien Tran, 2014, ACS medicinal chemistry letters.

Discovery and optimization of CRTH2 and DP dual antagonists.

T. Sullivan, G. Tonn, J. Medina, 2009, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a novel series of liver X receptor-alpha agonists.

J. Medina, B. Shan, Julio C Medina, 2006, Bioorganic & medicinal chemistry letters.

Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase.

R. Borch, J. Liu, J. Liu, 2000, Journal of medicinal chemistry.